{"groups":[{"description":"Participants with RRMM received GEN3014 at a dose of 0.2/0.6 milligrams per kilogram (mg/kg) by intravenous (IV) infusion in 28-day treatment cycles. Intraparticipant dose escalation was performed in this arm (i.e., dose was escalated from 0.2-0.6 mg/kg).","id":"FG000","title":"RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 2 mg/kg by IV infusion in 28-day treatment cycles.","id":"FG001","title":"RRMM Dose Escalation: GEN3014 2 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 4 mg/kg by IV infusion in 28-day treatment cycles.","id":"FG002","title":"RRMM Dose Escalation: GEN3014 4 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 8 mg/kg by IV infusion in 28-day treatment cycles.","id":"FG003","title":"RRMM Dose Escalation: GEN3014 8 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 16 mg/kg by IV infusion in 28-day treatment cycles.","id":"FG004","title":"RRMM Dose Escalation: GEN3014 16 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 24 mg/kg by IV infusion in 28-day treatment cycles.","id":"FG005","title":"RRMM Dose Escalation: GEN3014 24 mg/kg"},{"description":"Participants with R/R AML received GEN3014 at dose level 1 (low dose) in 28-day treatment cycles.","id":"FG006","title":"R/R AML Dose Escalation: GEN3014 Dose Level 1"},{"description":"Participants with anti-CD38 mAb-naive RRMM received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day cycles during Expansion Part A.","id":"FG007","title":"RRMM Expansion Part A: GEN3014"},{"description":"Participants with R/R DLBCL received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day cycles during Expansion Part A.","id":"FG008","title":"R/R DLBCL Expansion Part A: GEN3014"},{"description":"Participants with anti-CD38 mAb-naive RRMM received daratumumab at a dose of 1,800 mg by subcutaneous (SC) injection in 28-day treatment cycles.","id":"FG009","title":"RRMM Expansion Part B: Daratumumab"},{"description":"Participants with anti-CD38 mAb-naive RRMM received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day treatment cycles.","id":"FG010","title":"RRMM Expansion Part B: GEN3014"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"3"},{"groupId":"FG007","numSubjects":"5"},{"groupId":"FG008","numSubjects":"2"},{"groupId":"FG009","numSubjects":"9"},{"groupId":"FG010","numSubjects":"4"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"2"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"2"},{"groupId":"FG010","numSubjects":"6"}],"type":"Lost to Follow-Up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"0"}],"type":"Early Site Closure"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"4"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"30"},{"groupId":"FG010","numSubjects":"26"}],"type":"Sponsor Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"1"}],"type":"Started New Line Of Therapy Due To Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"1"}],"type":"Started New Line Of Treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"1"},{"groupId":"FG010","numSubjects":"7"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"11"},{"groupId":"FG005","numSubjects":"5"},{"groupId":"FG006","numSubjects":"5"},{"groupId":"FG007","numSubjects":"11"},{"groupId":"FG008","numSubjects":"2"},{"groupId":"FG009","numSubjects":"43"},{"groupId":"FG010","numSubjects":"45"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"11"},{"groupId":"FG005","numSubjects":"5"},{"groupId":"FG006","numSubjects":"5"},{"groupId":"FG007","numSubjects":"11"},{"groupId":"FG008","numSubjects":"2"},{"groupId":"FG009","numSubjects":"43"},{"groupId":"FG010","numSubjects":"45"}],"type":"Received at Least 1 Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"11"},{"groupId":"FG005","numSubjects":"5"},{"groupId":"FG006","numSubjects":"5"},{"groupId":"FG007","numSubjects":"11"},{"groupId":"FG008","numSubjects":"2"},{"groupId":"FG009","numSubjects":"43"},{"groupId":"FG010","numSubjects":"45"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"This study had 3 parts (Dose Escalation, Expansion Part A \\& Part B) and was terminated early. Due to enrollment challenges, the acute myeloid leukemia (AML) Dose Escalation and diffuse large B-cell lymphoma (DLBCL) Expansion Part A cohorts were terminated early. The anti-CD38 monoclonal antibody (mAb)-refractory relapsed or refractory multiple myeloma (RRMM) Cohort and relapsed or refractory (R/R) AML Cohort in Expansion Part A were not opened."}